Genor Biopharma Secures NMPA Approval for Lerociclib CDK4/6 Inhibitor in Advanced Breast Cancer
核心洞察
Genor Biopharma Holdings Ltd. (搜索) received China National Medical Products Administration (NMPA) approval for Lerociclib (GB491), a novel CDK4 (搜索)/6 inhibitor for advanced breast cancer treatment.
The oral bioavailable drug targets hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer in adult patients.
Lerociclib will be used in combination with aromatase inhibitors as initial therapy or with fulvestrant following endocrine therapy progression.
Genor Biopharma Holdings Ltd. (搜索) has achieved a significant regulatory milestone with the China National Medical Products Administration (NMPA) granting approval for its new drug application of Lerociclib (GB491), a novel cyclin-dependent kinases 4 and 6 inhibitor (CDK4 (搜索)/6i) developed in collaboration with G1 Therapeutics Inc.
Novel CDK4/6 Inhibitor for Breast Cancer Treatment
Lerociclib is characterized as a highly potent, selective oral bioavailable CDK4 (搜索)/6 inhibitor specifically designed for treating adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2 (搜索)-) locally advanced or metastatic breast cancer. The drug represents a targeted therapeutic approach for this specific breast cancer subtype.
Treatment Combinations and Clinical Applications
The approved indication encompasses two distinct treatment scenarios. Lerociclib will be administered in combination with an aromatase inhibitor as initial endocrine-based therapy for eligible patients. Additionally, the drug can be combined with fulvestrant in patients whose disease has progressed following previous endocrine therapy, providing a treatment option for patients with therapy-resistant disease.
Strategic Partnership and Development
The approval showcases the successful collaboration between Genor Biopharma and G1 Therapeutics Inc. in co-developing this novel therapeutic agent. This partnership has culminated in bringing a new treatment option to Chinese patients with advanced breast cancer, representing a significant achievement for both companies in the competitive oncology market.
The NMPA approval marks an important step in expanding treatment options for patients with HR+/HER2 (搜索)- advanced breast cancer in China, adding to the available arsenal of CDK4 (搜索)/6 inhibitors for this patient population.